Agrylin, Xagrid (anagrelide) is a small molecule pharmaceutical. Anagrelide was first approved as Agrylin on 1997-03-14. It is used to treat polycythemia vera and thrombocytosis in the USA. It has been approved in Europe to treat essential thrombocythemia. The pharmaceutical is active against cGMP-inhibited 3',5'-cyclic phosphodiesterase A.
|Indication||essential thrombocythemia, polycythemia vera, thrombocytosis|
|Drug Class||Platelet aggregation inhibitors|